The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy

The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy

ObjectiveTo investigate the predictive value of Controlling Nutritional Status (CONUT) score and systemic inflammation (SIS) score in the prognosis, short-term efficacy, and immune-related side effects of patient with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) receiving im...

Full description

Bibliographic Details
Main Authors:	Xiao-Han Zhao, Wen-Bin Shen, Duo Wang, He-Song Wang, Chun-Yang Song, Wen-Zhao Deng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Oncology
Subjects:	esophageal squamous cell carcinoma second-line treatment immune checkpoint inhibitors controlling nutritional status systemic inflammation score prognosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1167625/full

Similar Items

Corrigendum: The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy
by: Xiao-Han Zhao, et al.
Published: (2023-12-01)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
by: Xiaoyue Wu, et al.
Published: (2023-01-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
by: Ruixi Wang, et al.
Published: (2022-10-01)

Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
by: Xiao-Han Zhao, et al.
Published: (2023-09-01)

Metastatic squamous cell carcinoma of colon from esophageal cancer
by: Natasha Garg, et al.
Published: (2017-04-01)

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
by: Zhao J, et al.
Published: (2023-08-01)

Mucin 1 expression correlates with metastatic recurrence in postoperative patients with esophageal squamous cell cancer
by: Zhi-Gang Sun, et al.
Published: (2017-02-01)

Risk factors for metachronous esophageal squamous cell carcinoma after endoscopic or surgical resection of esophageal carcinoma: a systematic review and meta-analysis
by: Jie Du, et al.
Published: (2023-09-01)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Fenghao Shi, et al.
Published: (2022-11-01)

A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer
by: Qianhe Ren, et al.
Published: (2023-05-01)

Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma
by: Zongdan Jiang, et al.
Published: (2021-11-01)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
by: Yan Song, et al.
Published: (2021-05-01)

Comparative transcriptome characterization of esophageal squamous cell carcinoma and adenocarcinoma
by: Xianfeng Li, et al.
Published: (2023-01-01)

Unusual Presentation of a Metastatic Esophageal Carcinoma
by: Katarzyna Orlicka, et al.
Published: (2012-05-01)

Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?
by: Hannah Christina Puhr, et al.
Published: (2021-09-01)

Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data
by: Kim Y, et al.
Published: (2023-05-01)

Research Progress of Predictive Markers for Efficacy of Immune Checkpoint Inhibitors for Esophageal Squamous Cell Carcinoma
by: CHEN Rongshan, et al.
Published: (2022-12-01)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01)

Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis
by: Tian-Tian Gao, et al.
Published: (2022-09-01)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
by: Ying Li, et al.
Published: (2022-12-01)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Christian Borel, et al.
Published: (2020-09-01)

Overexpression of JAB1 promotes malignant behavior and predicts poor prognosis in esophageal squamous cell carcinoma
by: Qi Shen, et al.
Published: (2020-04-01)

High Serum Elafin Prediction of Poor Prognosis of Locoregional Esophageal Squamous Cell Carcinoma
by: I-Chen Wu, et al.
Published: (2021-06-01)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
by: Shao-Wu Jing, et al.
Published: (2022-10-01)

Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma
by: Gang Ji, et al.
Published: (2024-04-01)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
by: Yi-Min Gu, et al.
Published: (2021-12-01)

Lymph node metastatic patterns and its clinical significance for thoracic superficial esophageal squamous cell carcinoma
by: An Wang, et al.
Published: (2020-09-01)

Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy
by: Junchao Qian, et al.
Published: (2022-04-01)

Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response
by: Chen Ling, et al.
Published: (2022-05-01)

Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
by: Jiang-Qiong Huang, et al.
Published: (2024-03-01)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
by: Huilai Lv, et al.
Published: (2023-01-01)

BAG2 overexpression correlates with growth and poor prognosis of esophageal squamous cell carcinoma
by: Hong Ying-Cai, et al.
Published: (2018-12-01)

The CONUT score is prognostic in esophageal cancer treated with chemoradiotherapy
by: Metin Demir, et al.
Published: (2023-01-01)

Overexpression of VEGF-C and MMP-9 predicts poor prognosis in Kazakh patients with esophageal squamous cell carcinoma
by: Jiangfen Li, et al.
Published: (2019-12-01)

Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation
by: Hongmu Li, et al.
Published: (2023-04-01)

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
by: Zhihao Lu, et al.
Published: (2022-05-01)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
by: Hongfu Cai, et al.
Published: (2021-11-01)

Overview of Risk Factors for Esophageal Squamous Cell Carcinoma in China
by: Erica Conway, et al.
Published: (2023-11-01)

Esophageal squamous cell carcinoma presenting as a submucosal tumor
by: Lin Yang, et al.
Published: (2023-08-01)